-
Article
Histoculture drug response assay for gefitinib in non-small-cell lung cancer
There are many predictive factors for gefitinib sensitivity, including epidermal growth factor receptor (EGFR) gene mutation, EGFR copy number, and k-ras mutation. To investigate all of them is too expensive. We ...
-
Article
In vitro evaluation of dose-response curve for paclitaxel in breast cancer
The dose-response curve for anticancer agents cannot be evaluated by studying patients directly. To investigate individual differences in the dose-response curve for paclitaxel in breast cancer, we utilized th...
-
Article
Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size
Non-surgical ablation is an attractive approach as a local control method for breast cancer. The purpose of this study was to investigate the complications and efficacy of radiofrequency ablation (RFA) therapy...
-
Article
A case of serum CEA disappearance curve after resection of breast carcinoma
Carcinoembryonic antigen (CEA) elimination kinetics after tumor resection were measured in a case of breast cancer. A 45-year-old woman with a left breast carcinoma underwent surgery after neoadjuvant chemothe...
-
Article
Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer
Bisphosphonates inhibit osteoclastic bone resorption and are being used as treatment for bone metastases from breast cancer. Intravenous bisphosphonate therapy can significantly reduce skeletal related events ...
-
Article
A case of granulomatous mastitis mimicking breast carcinoma
A 58-year-old woman presenting with idiopathic granulomatous mastitis mimicking breast carcinoma is described. The mass was elastic, hard and painless, and located in the upper outer quadrant of the right brea...
-
Article
Bisphosphonate therapy for bone metastases from Breast Cancer: Clinical results and a new therapeutic approach
We evaluated the usefulness of bisphosphonate (BIS) monotherapy, the safety of rapid infusion of BIS and the efficacy of BIS-sequential therapy for bone metastases from breast cancer.